Belite Bio (BLTE) said Thursday that an independent data safety monitoring board has advised continuing the phase 3 Dragon trial of Tinlarebant for adolescent Stargardt disease without altering the study's structure.
The recommendation to continue followed an interim analysis after all 104 participants completed a year of treatment and is expected to finish by Q4 without an increase in sample size, the company said.
Belite Bio also said Tinlarebant has shown a consistent safety profile, with no significant adverse effects reported, and most participants experienced stable vision that improved from baseline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.